Tags: Drug.

Vatalanib (INN codenamed PTK787 or PTK/ZK) is a small molecule protein kinase inhibitor that inhibits angiogenesis. It is being studied as a possible treatment for several types of cancer particularly cancer that is at an advanced stage or has not responded to chemotherapy. Vatalanib is orally active that is it is effective when taken by mouth.Vatalanib is being developed by Bayer Schering and Novartis.

Vatalanib.svg
ATC prefix
none
CAS number
212141-54-3
FDA UNII code
5DX9U76296
IUPAC name
N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin- 1-amine
PubChem
151194

Loading...

This page contains content from the copyrighted Wikipedia article "Vatalanib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.